In connection with the implementation of the project entitled ‘Design and development of nanoparticle-RNA based drugs to be used in anti-cancer therapy with the construction of a nanoparticle platform for targeted delivery of therapeutic nucleic acids’, by BS Biotechna SA, within the framework of agreement no. 2022/ABM/06/00005-00 for co-financing of the Commercial Project within the framework of the Competition for the development of targeted or personalised medicine based on therapeutic products based on nucleic acids and small-molecule compounds, the Ordering Party is making a market inquiry concerning the cost of purchasing DLin-MC3-DMA ionisable lipid.
In order to submit an offer, please read the detailed content of the notice on request for quotation 13/2025 and send us the completed offer form.